Abstract: The present invention relates to improved single domain antibodies that target SARS-CoV-2, multivalent polypeptides and fusion proteins comprising the single domain antibodies. The present invention also provides coronavirus binding molecules that bind two different epitopes on the receptor binding domain of a spike protein of a coronavirus. The coronavirus binding molecules are based on joining two antigen binding molecules together via a linker. The present invention provides the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in treating and/or preventing coronavirus, as well as the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in the detection and diagnosis of coronavirus using various methods, assays and kits.

Abstract: The present invention relates to improved single domain antibodies that target SARS-CoV-2, the use of said single domain antibodies in treating and/or preventing coronavirus, as well as the use of said single domain antibodies in the detection and diagnosis of coronavirus using various methods, assays and kits.

Abstract: This invention relates to an engineered leader-independent heterocyclase (also known as a cyclodehydratase) comprising a defined cyanobactin leader sequence which drives the efficient conversion of heterocyclisable amino acids, such as Ser, Thr and Cys, within a peptide substrate lacking a leader sequence into heterocycles produce a homogenous heterocycle-containing product. This may be useful in biotechnology and chemical synthesis.

Abstract: This invention relates to the in vitro production of cyclic peptides using cyanobacterial enzymes, such as patellamide biosynthesis enzymes. Linear peptide substrates are cyclized using an isolated cyanbacterial macrocyclase, such as PatG from Prochloron spp. Before cyclization, residues in the linear peptide substrates may be heterocyclized using isolated cyanbacterial heterocyclasses, such as PatD or TruD heterocyclase. Methods of the invention may be useful, for example, for the production of cyclic peptidyl molecules, including cyclotides, such as katalas, and cyanobactins, such as patellamides and telomestatins, for example for use in the development of therapeutics.

Abstract: This invention relates to an engineered leader-independent heterocyclase (also known as a cyclodehydratase) comprising a defined cyanobactin leader sequence which drives the efficient conversion of heterocyclisable amino acids, such as Ser, Thr and Cys, within a peptide substrate lacking a leader sequence into heterocycles produce a homogenous heterocycle-containing product. This may be useful in biotechnology and chemical synthesis.

Abstract: This invention relates to the in vitro production of cyclic peptides using cyanobacterial enzymes, such as patellamide biosynthesis enzymes. Linear peptide substrates are cyclized using an isolated cyanbacterial macrocyclase, such as PatG from Prochloron spp. Before cyclisation, residues in the linear peptide substrates may be heterocyclised using isolated cyanbacterial heterocyclasses, such as PatD or TruD heterocyclase. Methods of the invention may be useful, for example, for the production of cyclic peptidyl molecules, including cyclotides, such as katalas, and cyanobactins, such as patellamides and telomestatins, for example for use in the development of therapeutics.

Abstract: This invention relates to the in vitro production of cyclic peptides using cyanobacterial enzymes, such as patellamide biosynthesis enzymes. Linear peptide substrates are cyclized using an isolated cyanbacterial macrocyclase, such as PatG from Prochloron spp. Before cyclisation, residues in the linear peptide substrates may be heterocyclised using isolated cyanbacterial heterocyclases, such as PatD or TruD heterocyclase. Methods of the invention may be useful, for example, for the production of cyclic peptidyl molecules, including cyclotides, such as katalas, and cyanobactins, such as patellamides and telomestatins, for example for use in the development of therapeutics.

Abstract: There is provided a method of obtaining selecting agents which inhibit the enzyme glucose-1-phosphate thymidylyltransferase (Rm1A) based upon analysis of a model of the active and regulatory site (s) of Rm1A and interaction therewith by a potential inhibitory agent. The invention is based upon the provision of information on the structure of Rm1A obtained through X-ray diffraction studies since a crystallised form of Rm1A was obtained for the first time. The purified and crystallised from of Rm1A, obtained from Psemdomononas aeruginosa is also described.